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The term small for gestational age (SGA) refers to infants whose birth weights and/or lengths are at least two
standard deviation (SD) units less than the mean for gestational age. This condition affects approximately 3%–10%
of newborns. Causes for SGA birth include environmental factors, placental factors such as abnormal uteroplacental
blood flow, and inherited genetic mutations. In the past two decades, an enhanced understanding of genetics has
identified several potential causes for SGA. These include mutations that affect the growth hormone (GH)/insulin-like
growth factor (IGF)-1 axis, including mutations in the IGF-1 gene and acid-labile subunit (ALS) deficiency. In addition,
select polymorphisms observed in patients with SGA include those involved in genes associated with obesity, type 2
diabetes, hypertension, ischemic heart disease and deletion of exon 3 growth hormone receptor (d3-GHR)
polymorphism. Uniparental disomy (UPD) and imprinting effects may also underlie some of the phenotypes observed
in SGA individuals. The variety of genetic mutations associated with SGA births helps explain the diversity of phenotype
characteristics, such as impaired motor or mental development, present in individuals with this disorder. Predicting the
effectiveness of recombinant human GH (hGH) therapy for each type of mutation remains challenging. Factors
affecting response to hGH therapy include the dose and method of hGH administration as well as the age of initiation
of hGH therapy. This article reviews the results of these studies and summarizes the success of hGH therapy in treating
this difficult and genetically heterogenous disorder.
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Uniparental disomyDefinition and epidemiology of small for
gestational age (SGA)
Despite past inconsistencies in defining small for gesta-
tional age (SGA) (as reviewed by Saenger et al [1]) the
International Societies of Pediatric Endocrinology and the
Growth Hormone Research Society, as well as the Inter-
national Small for Gestational Age Advisory Board,
recently recommended that the term refer to infants
whose birth weights and/or lengths are at least two stand-
ard deviation (SD) units less than the mean for gestational
age [2,3]. According to this definition, approximately 3%–
10% of newborns are considered SGA at birth, although it
should be noted that new intrauterine growth curves* Correspondence: phsaenger@gmail.com
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distribution, and reproduction in any mediumcreated with a more contemporary, larger, and more
racially diverse population suggest that many SGA
patients are often misclassified as appropriate for gesta-
tional age (AGA) [4]. While most of these infants undergo
catch-up growth, 10%–15% remain small for their age at
the age of 2 years [5-8]. In 2001, human growth hormone
(hGH) therapy using dose regimens up to 48 mcg/kg/
week [3] was approved by the United States (US) Food
and Drug Administration (FDA) to treat SGA patients
greater than 2 years old. However, because the causes of
SGA are diverse, hGH treatment outcomes vary among
patients. Thus, identifying the underlying mechanisms for
SGA births may help predict patient response to hGH
therapy. Causes for SGA births, which are summarized in
Table 1 [3,4], involve environmental factors, placental fac-
tors such as abnormal uteroplacental blood flow, or inher-
ited genetic mutations [3,4]. Over the last two decades,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Factors associated with increased incidence of SGA birth
Fetal Maternal Uterine/Placental Demographic
Karyotypic Medical conditions Gross structural placental factors Maternal age
-Trisomy 21 -Hypertension -Single umbilical artery -Very young age
-Trisomy 18 -Renal disease -Placental hemangiomas -Older age
-Monosomy X -Diabetes mellitus -Infarcts, focal lesions Maternal height
-Trisomy 13 -Collagen vascular diseases Insufficient uteroplacental perfusion Maternal weight
Chromosomal abnormalities -Maternal hypoxemia -Suboptimal implantation site Maternal and paternal race
-Autosomal deletion Infection Placenta previa History of SGA
-Ring chromosomes -Toxoplasmosis Low-lying placenta














HIV, human immunodeficiency virus; SGA, small for gestational age.
Reprinted with permission from [3].
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ence SGA has been conducted, and this article reviews the
results of these studies and summarizes the success of
hGH therapy in treating this condition. It should be men-
tioned at the beginning of this review, however, that the
number of genetic variations for any particular gene that
has been associated with SGA birth does not necessarily
correlate with the number of patients who have this de-
fect. For instance, four different genetic mutations in the
distal region of the terminal long arm of chromosome 15
linked with SGA birth size will be described, while only
two mutations are illustrated for patients born SGA with
Silver-Russell syndrome (SRS). However, this does not
mean that SGA patients are two times more likely to have
a mutation in the distal region of chromosome 15 than a
mutation associated with SRS. Of note, a website from the
Growth Genetics Consortium, an international collabor-
ation, gathers all current information about genetic syn-
dromes disrupting the growth hormone and insulin-like
growth factor (IGF) axis [9]. Cases reported involve the
following genes: GHR, GHRHR, STAT5B, IGF1, IGF2,
IGFALS, and IGF1R. Forty-eight cases have been
approved for inclusion into the database so far. This paper
aims to illustrate the variety of genetic mutations that areassociated with SGA births while concurrently describing
how other phenotype characteristics of the patient, such
as motor or mental development, can vary depending on
which mutation was inherited.
Genetic factors influencing SGA
GH/IGF-1 axis
IGF-1 gene
Transcription of the gene for IGF-1 is mediated by the
binding of pituitary GH to specific GH receptors on hepa-
tocytes. The secretion of IGF-1 from the liver then stimu-
lates cell growth (particularly bone) and inhibits secretion
of GH from the pituitary [10]. Consequently, mutations of
the IGF-1 gene affect growth and GH secretion and have
been correlated with SGA births. A homozygous partial
deletion of exons 4 and 5 of IGF-1 was observed for one
patient born SGA. The mutation truncated the IGF-1 pep-
tide sequence from 70 to 25 amino acids and was followed
by an out-of-frame nonsense sequence and stop codon. In
addition to growth defects, the patient suffered from bilat-
eral sensorineural deafness and mental retardation, a fea-
ture indicating the importance of IGF-1 in central nervous
system development [11]. When treated with hGH at a
0.1 U/kg dose for 4 days, no detectable IGF-1 level could
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recombinant human IGF-1 (rhIGF-1) therapy for one year
(three months at 40 mcg/kg/day, nine months at 80 mcg/
kg/day), insulin sensitivity, bone mineral density, and line
growth of this patient were improved [12].
A second patient born SGA with sensorineural deafness
and mental retardation was evaluated for IGF-1 defects. Inves-
tigators observed a T!A transversion in the 3′-untranslated
region of exon 6 that caused the expression of a truncated ver-
sion of exon 6 and an altered E domain of the IGF-1 prohor-
mone. hGH therapy for this patient (200 mcg hGH/day
intramuscular doses for seven days) afforded no improvement
in IGF-1 levels [13]. It should be noted that a second research
group later sequenced IGF-1 (exons 1–6) in 53 children born
SGA and determined that none of the mutations in the cod-
ing region of IGF-1 correlate with SGA stature [14].
Similarly, an IGF-1 defect was observed for a third patient
who had initially been evaluated at the age of 21 years for
SGA birth size [15]. In addition to SGA size, the patient ini-
tially presented with bilateral hearing loss, microcephaly,
and severe mental retardation. When investigators re-
evaluated the patient at 55 years of age, unusually high
serum levels of IGF-1 were noted, which varied from the pa-
tient phenotypes described by Woods and Bonapace [11-
13]. Furthermore, both insulin-like growth factor binding
protein-3 (IGFBP-3) and insulin-like growth factor-1 recep-
tor (IGF-1R) levels were normal. However, by sequencing
IGF-1, investigators detected a nucleotide substitution at
position 274 (G!A) in the sequence, which caused an
amino acid substitution at position 44 of the IGF-1 protein
(V44M). The modified IGF-1 protein displayed a 90-fold-
lower binding affinity for IGF-1R than the wild-type deriva-
tive, although the mutated protein had normal binding cap-
acity for IGFBPs. This reduced affinity of IGF-1 for IGF-1R
resulted in diminished phosphorylation of IGF-1R and
downstream-acting signaling proteins, particularly Akt/PKB
[16,17].
Finally, when a fourth patient born SGA in length and
weight was evaluated for IGF-1 defects, investigatorsTable 2 Phenotypic characteristics and response to hGH thera
Genetic mutation Phenotype
Deletion of exons 4 and 5 Birth weight −3.9 SD; birth length −5
sensorineural deafness and mental re
nearly undetectable IGF-1 levels
Truncated version of exon 6 Birth weight −4 SD; birth length −6.5
sensorineural deafness and mental re
low serum IGF-1 levels
V44M Birth weight −3.9 SD score; birth leng
bilateral hearing loss, microcephaly, s
elevated GH levels and IGF-1 levels b
R36Q Birth weight −2.5 SD score; birth leng
mild mental development delay; redu
but increased IGFBP-3 levels
hGH, human growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-likdiscovered a homozygous G!A missense mutation in the
gene that caused replacement of arginine by a glutamine
at position 36 (R36Q) in the C domain of the correspond-
ing IGF-1 protein. This change decreased the binding af-
finity of IGF-1 for IGF-1R by nearly three-fold, but
normal affinity for IGFBP-3 was maintained [18,19]. This
study confirmed that IGF-1 mutations that lead to only
partial loss of IGF-1 protein activity can cause significant
postnatal as well as prenatal growth defects. While high-
dose hGH therapy (400 mcg/kg/week) promoted success-
ful catch-up growth, the patient’s treatment modality was
recently changed to rhIGF-1 therapy [20]. It should be
noted that rhIGF-1 therapy has only been approved by the
US FDA to treat patients with severe primary IGF-1 defi-
ciency or patients with GH gene deletions who have
developed neutralizing antibodies to GH [21]. The
genotype-phenotype correlations and response to hGH
therapy for each of these patients expressing IGF-1 muta-
tions is summarized in Table 2 [11,13,16-18].
IGF-1R
Various compound heterozygous mutations throughout
the coding sequence of IGF-1R have been described for
multiple families, with each case exhibiting phenotype var-
iations [22]. Typically, IGF-1R mutations can be classified
as point mutations or partial deletions. When one patient
born SGA with significantly delayed postnatal growth was
evaluated for IGF-1R mutations, investigators determined
that two point mutations in exon 2 of IGF-1R caused two
single-base pair substitutions in the codons for amino acid
108 (CGG!CAG) and 115 (AAA!AAC) of the corre-
sponding protein. This change resulted in two-thirds-lower
binding affinity of IGF-1 to IGF-1R in fibroblasts as com-
pared with controls. When treated with hGH therapy (37.5
mcg/kg/week), the patient’s growth rate was increased to
the 75th percentile for her age [23].
Similarly, a second patient born SGA who suffered
from postnatal growth delay, microcephaly, and mild
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e growth factor binding protein-3; n.a., not available; SD, standard deviation.
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Ter) in exon 2 of IGF-1R caused early termination of
transcription of the IGF-1R protein, leading to reduced
receptor expression on the cell surface, as well as
decreased autophosphorylation and phosphorylation of
signaling proteins [23]. When treated with hGH at 30
mcg/kg/day starting at age 6 years, the patient’s height
increased by 1.01 SD after two years of therapy, indicat-
ing that hGH therapy can improve quality of life for
SGA patients with this mutation [24].
When 24 children born SGA were evaluated by direct
sequencing of IGF-1R to identify causal mutations, two
patients were observed to have a heterozygous missense
mutation (C!T) of IGF-1R, which altered the cleavage
site of the proreceptor of IGF-1R from RLRR to RLQR
(R709Q). This mutation inhibited the expression of mature
IGF-1R from the IGF-1R precursor protein. Interestingly,
the two patients who presented with this mutation had
different levels of mental development. While patient 1
displayed mental retardation, patient 2 had normal intel-
lectual development. Thus, no link exists between the
heterozygous IGF-1R mutation and intellectual develop-
ment [25].
Similarly, two more patients were evaluated and deter-
mined to present with a missense mutation in the intra-
cellular kinase domain of IGF-1R. The older patient, a
35-year-old mother, showed above-average intelligence
and no dysmorphic features, but her height (−4.0 SD
score) and head circumference (−3.0 SD score) showed
growth retardation. Her daughter, patient 2, was born
SGA and showed normal mental development but
delayed motor development by the age of 15 months.
Both patients showed increased IGF-1 levels. Sequence
analysis of IGF-1R showed a heterozygous G!A nucleo-
tide substitution, which changed the amino acid se-
quence of IGF-1R at position 1050 from glutamic acid
to lysine. This mutation did not affect expression of
IGF-1R protein, but the sequence alteration reduced
autophosphorylation of IGF-1R and activation of PKB/
Akt [26]. Similarly, a 13.6-year-old girl who displayed short
stature (−5.0 SD score) and reduced bone age (9.7 years), as
well as elevated IGF-1 levels and no improvement in height
following six months of treatment with hGH therapy at a
daily dose of 70 mcg/kg/day, was evaluated for IGF-1R
mutations. A heterozygous G!A point mutation at pos-
ition 1577 of IGF-1R resulted in substitution of arginine
with glutamine at residue 481 of the corresponding protein
(R481Q). This mutation altered the α-subunit of IGF-1R,
leading to reduced phosphorylation and cell growth [27].
Recently, a third report has described a similar IGF-1R mu-
tation in which alanine replaced glycine at position 1125 in
seven patients from the same family, causing reduced re-
ceptor autophosphorylation and phosphorylation of down-
stream kinases [28].Finally, a patient born SGA with high IGF-1 levels who
showed only marginal improvement in height following
treatment with hGH therapy at the age of 7.4 years (doses
ranging from 31 to 36 mcg/kg/day) was evaluated for IGF-
1R mutation. Gene sequencing showed heterozygous T!A
mutation at position 1886, which resulted in substitution
of valine with glutamic acid at position 599 of the protein
(V599E). This mutation interfered with the receptor traf-
ficking pathway, diminishing the density of the receptor on
the cell surface [29]. The genotype-phenotype correlations
and response to hGH therapy for each of these patients
expressing IGF-1R point mutations is summarized in
Table 3 [23,25-29].
In addition to point mutations, distal deletions of the
terminal long arm of chromosome 15 have also been
linked to patients born SGA, although these mutations
are quite rare. Often, these patients present with symp-
toms resembling Prader-Willi or Angelman syndrome,
two diseases resulting from deletions in the 15q11q13 re-
gion [30]. One patient born SGA who exhibited continued
growth retardation at the age of 4.5 years was evaluated
for such distal deletion. It was determined that the patient
presented with partial monosomy 15q26.2!15qter, cor-
relating to a deleted critical region of approximately
5.7 Mb [31]. This deletion includes the region 15q26.3, to
which the IGF-1R gene has been assigned [32]. A similar
deletion was observed for a patient born SGA who dis-
played a heterozygous 8.58 Mb deletion in the same re-
gion [33]. Similarly, a patient born SGA who showed
significant growth retardation by the age of 2 years was
evaluated for deletions in chromosome 15. Results indi-
cated that the maternally derived chromosome 15 had a
4.7 Mb deleted region, which included 15q26.2 [34]. The
smallest deletion of chromosome 15 that has been
observed to cause SGA birth involves a mutation in exons
11–21 of the IGF-1R gene (a 0.095 Mb deletion) and was
associated with SGA births over three generations in a
single family [35]. Typically, patients with partial deletions
in this region display mental and psychomotor develop-
mental retardations more often than patients with point
IGF-1Rmutations [22].
Fortunately, patients with partial deletions of chromo-
some 15 respond favorably to hGH treatment. A patient
born SGA who displayed a heterozygous loss of
15q26.2!15qter began hGH treatment at the age of
5.3 years at a dose of 1 mg/m2/day (approximately 30
mcg/kg/day). Rapid growth catch-up was observed, and
by the age of 15 years the patient had nearly reached her
target height (−1.6 SD score) [36]. Similarly, two patients
displaying deletions in exons 1–21 and exons 3–21 were
treated with hGH therapy at a dose of 1 mg/m2/day (ap-
proximately 30 mcg/kg/day). For both patients, treat-
ment resulted in moderate increase in height of
approximately +1 SD after one year [37].
Table 4 Genetic mutations involved in ALS deficiency [39-47]

















S195_R197dup In-frame insertion of
3 amino acids, SLR
Compound heterozygous
L241P Missense Compound heterozygous
L244F Missense Compound heterozygous
N276S Missense Homozygous
Q320X Nonsense Homozygous
L437_L439dup In-frame insertion of







C540R Missense Compound heterozygous
ALS, acid-labile subunit.
Table 3 Phenotypic characteristics and response to hGH therapy for patients with IGF-1R mutations
Genetic mutation Phenotype GH response References
R108Q
K115N
Birth weight −3.5 SD score; delayed motor skill development;




R59X Birth weight −3.5 SD score; birth length −5.8 SD score;








E1050K Birth height −0.3 SD score, birth weight −2.1 SD score;
height at 35 years −4.0 SD score; head circumference at 35 years
−3.0 SD score; no dysmorphic features; high IGF-1 levels
N/A Walenkamp,
2006 [26]
R481Q Height −4.9 SD score, reduced bone age, elevated IGF-1 levels − Inagaki,
2007 [27]
G1125A Birth weight −1.7 SD score; head circumference at
birth −3.7 SD score; normal mental development
N/A Kruis,
2010 [28]
V599E Birth weight −2.3 SD score; birth head circumference
<3rd percentile; high IGF-1 levels; mental retardation
− Wallborn,
2010 [29]
hGH, human growth hormone; IGF-1, insulin-like growth factor-1; N/A, not available; SD, standard deviation.
Saenger and Reiter International Journal of Pediatric Endocrinology 2012, 2012:12 Page 5 of 12
http://www.ijpeonline.com/content/2012/1/12Acid-Labile Subunit (ALS) Deficiency
In serum, IGF-1 circulates in complex with IGFBP-3 or
IGFBP-5 and an ALS, an 85-kDa glycoprotein that func-
tions to prolong the half-life of the IGF-IGFBP-3/IGFBP-5
binary complex [38]. Sixteen different mutations of the
IGFALS gene, located at 16p13.3 on chromosome 16, have
been observed in patients who presented with reduced
postnatal growth. The type of IGFALS gene mutation var-
ies, including missense, nonsense, deletion, duplication
and insertion that cause frameshift and premature stop
codons, and in-frame duplication mutations, but nearly all
of the mutations show autosomal recessive pattern of
inheritance and cause defects in the leucine-rich repeat
region of the corresponding ALS protein (Table 4) [39-
47]. All of these mutations result in circulating ALS levels
that are barely detectable based on enzyme-linked immu-
noabsorbent assay, radioimmunoassay, or Western immu-
noblot assays, indicating that the mutations likely inhibit
the corresponding protein from being secreted by the liver
or cause the protein to degrade rapidly after secretion.
The circulating ALS deficiency results in a severe reduc-
tion in IGF-1 and IGFBP-3 levels, insulin insensitivity, and
pubertal delay. hGH therapy was initiated for some of
these patients in an effort to increase growth rate. How-
ever, despite the treatments, ranging in duration from six
months to more than two years, very little growth re-
sponse was observed. However, it has been suggested that
hGH therapy may be beneficial for heterozygous carriers
who still carry one intact IGFALS allele.
Select polymorphisms
Obesity and diabetes
For many individuals born SGA, health concerns such as
obesity, type 2 diabetes, hypertension, and ischemic heartdisease are often encountered later in life [48-50]. In one
study, DNA samples from 546 patients (227 children born
SGA and 319 born AGA) were analyzed for 54 single nucleo-
tide polymorphisms (SNPs) associated with diabetes or obes-
ity. Genetic variations in five of these SNPs (KCNJ11, BDNF,
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fore, genetic factors that contribute to obesity and type 2 dia-
betes likely correlate with SGA [51].
Angiotensinogen gene variants
Angiotensinogen (AGT) is an α2-globulin precursor to
angiotensin II that regulates blood pressure and overall
homeostasis [52]. In one study, 174 women and their
162 infants born SGA were compared with 400 women
and their 240 infants born AGA. The study evaluated
these individuals for a methionine to threonine substitu-
tion at codon 235 (235Met >Thr) in the AGT gene, a
mutation associated with pregnancy complications such
as preeclampsia [53]. The results showed a higher fre-
quency of the 235Thr allele in both mothers (0.60 for SGA
versus 0.36 for controls) and infants (0.59 for SGA versus
0.38 for controls) who were associated with SGA births
[54]. However, the mechanism by which the 235Met >Thr
mutation affects maternal-placental and fetal-placental cir-
culation and, consequently, fetal growth is not understood.
Interestingly, a prior study found no correlation between
this polymorphism and an increased risk of SGA birth. The
differences between the findings of the two investigations
were attributed, in part, to variation in ethnic diversity be-
tween the two study groups [55].
Deletion of exon 3 growth hormone receptor (d3-GHR)
The d3-GHR polymorphism, a 2.7 kB deletion in exon 3 of
the GHR gene, is a common genetic defect in individuals
with normal height and those born SGA [56]. However, for
patients born SGA, the d3-GHR polymorphism has been
investigated as a potential mutation that affects hGH ther-
apy due to its role in GH signaling. When response to
hGH therapy was compared between children born SGA
who had only full-length GHR versus at least one d3-GHR
allele, results showed that patients with the d3-GHR poly-
morphism responded 1.7 to 2 times better to hGH therapy
than patients with only the full-length gene [57]. Similarly,
SGA patients with either two full-length GHRs (fl/fl) or one
(d3/fl) or two (d3/d3) d3-GHR alleles were administered
hGH for 12 months at a mean dose of 56±11 mcg/kg/day.
At the end of 12 months, carriers of either one or two d3-
GHR alleles were observed to respond slightly better to
hGH therapy than patients with two full-length alleles, al-
though the difference was not statistically significant. The
authors suggested that response to hGH therapy for
patients with this mutation depends on the specific causes
of short stature, such as IGF-1 insensitivity or IGF-1
deficiency [58]. Consequently, children born SGA with the
d3-GHR mutation appear to be prime candidates for hGH
therapy, although these results are still controversial.
For instance, a comparison was made between the GHR
genotype (ie, fl/fl, d3/fl, or d3/d3) of patients with GH
deficiency and the individual’s response to hGH treatment.Patients were treated with hGH at a mean dose of 0.2 mg/
kg/week for one year and then evaluated for height SD
score, height velocity, and height velocity SD score. No
statistically significant difference with respect to the mea-
sured outcomes could be observed between the patients
with the d3-GHR allele and patients who were homozy-
gous for the full-length GHR. Furthermore, this study
observed that there was no relationship between an indivi-
dual’s baseline phenotype and his/her GHR genotype, sug-
gesting that the d3-GHR allele does not affect height in
GH deficiency [59]. This lack of correlation between d3-
GHR genotype and response to hGH treatment was also
confirmed in studies for patients born SGA [60,61].
Recently, a meta-analysis of 15 studies investigating the
effects of d3-GHR genotype and a patient’s first-year
response to hGH therapy, including height gain and
change in growth velocity, was conducted. The results of
this analysis indicated that patients with the d3-GHR allele
showed improved growth velocity when treated with hGH
therapy, but the treatment outcome was affected by the
dose (low doses of hGH showed best response) and age at
time of treatment (older patients responded more favor-
ably). It should be noted, however, that this meta-analysis
did not discriminate with respect to the cause of short
stature [62]. In a recent 3-year review, Doerr et al con-
clude that the determination of GHR isoforms for deletion
of exon 3 is not particularly useful in defining the overall
response to GH in short SGA children [63].
Uniparental disomy (UPD) and imprinting effects
UPD is a process whereby a person inherits two copies
of a gene or chromosome from one parent and no cop-
ies from the other parent. In most cases, UPD does not
affect fetal development. However, if a UPD gene is also
an imprinted gene, there may be adverse effects to the
fetus, because UPD of imprinted genes is equivalent to
functional nullisomy [64]. The transcriptional regulation
of imprinted genes varies from normal genes in that
imprinted genes are only active from one parent allele.
For instance, a gene may be active only when paternally
inherited; the maternal allele of this gene is “switched
off.” Conversely, imprinted genes can be maternally
expressed and paternally imprinted [65]. Thus, if a pa-
tient inherits two versions of an imprinted gene (eg, two
copies of a maternal, “switched-off” gene), phenotype ab-
normalities may result. Studies have indicated that sev-
eral UPDs can be responsible for short stature in
patients born SGA.
SRS
SRS is a disorder characterized by reduced birth weight,
facial features including triangular shape and pointed
chin, and body asymmetry [66,67]. Growth restrictions
continue through life and often correlate with fasting
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cutaneous injections at a dose of 35 mcg/kg/day for up to
three years, is usually suggested for these patients [69].
The genetic causes of SRS vary, with cases of
autosomal-dominant, autosomal-recessive, and X-linked
inheritance all observed (as reviewed by Hitchins and
Abu-Amero) [68,70]. However, the most referenced
causal candidates for this disease involve mutations on
chromosomes 7 and 11, which both contain groups of
genes that undergo genomic imprinting [68]. Since the
early 1990s, maternal uniparental disomy 7 (mUPD7),
both full mUPD7 and mUPD for the long arm of
chromosome 7, were documented to be the cause of
SRS in approximately 10% of cases [71]. However, the
phenotype of an SRS patient presenting UPD7 cannot be
predicted, as the exact etiology of the mutation varies
[72]. Polymerase chain reaction with microsatellite re-
peat markers or Southern blot analysis with variable
number of tandem repeats can effectively be used to
screen patients for mUPD7 [73].
In addition to mUPD7, the imprinted region on
chromosome 11p15 has been associated with SRS in up
to 65% of patients. Specifically, hypomethylation at the
imprinting center region 1 (ICR1) was associated with
fetal growth retardation in SRS patients (Figure 1)
[74,75]. Generally, the ICR1 region regulates the expres-
sion of IGF2 and H19, and loss of methylation of this re-
gion is associated with approximately 50% of SRS cases
[68]. However, an inherited duplication (0.76 – 1 Mb) in
the ICR2 domain of 11p15 has also been shown to be
involved in the etiology of SRS. The duplicated region
included the maternally expressed genes KCNQ1,
CDKN1C, TSSC5/SLC22A8 and TSSC3/PHDLA2 and
the paternally expressed gene LIT1 [76]. It should be
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Figure 1 Quantitative representation of methylation indices for
H19-IGF2 ICR1 in individuals with SRS (individuals 1–9 and
individual 6’s twin) and an individual with isolated
hypermethylation of the H19 promoter (BWS1). Five individuals
with SRS displayed partial loss of H19-IGF2 ICR1, indicated by the bar
below the shaded area near 50%. SRS, Silver-Russell syndrome.
Reprinted from [74] with permission from Macmillan Publishers Ltd;
copyright 2005.values among patients with SRS is quite varied, making
clinical diagnosis of the disease based on methylation
analysis difficult [77]. In general, use of hGH has be-
come a standard treatment regimen for patients with
SRS, despite the limited number of evaluations regarding
the effectiveness of this treatment [78].
mUPD
UPD of the long arm of chromosome 14 (UPD14) has
been associated with both below-average growth and
mental retardation. Initially, it was not known whether
the congenital anomalies present in UPD14 patients
resulted from an extra copy of an active imprinted gene
(ie, two genes that were “switched on”) or the absence of
gene expression caused by the presence of two repressed
alleles (ie, two genes “switched off”). To determine the
likely cause of the phenotype, patients with distal partial
trisomy for chromosome 14 (Ts14) were evaluated to de-
termine genotype-phenotype correlations to determine
whether the partial trisomy was of maternal or paternal
origin. By investigating patients with an extra copy of ei-
ther maternally inherited or paternally inherited copies
of chromosome 14, the investigators hoped to observe
more pronounced effects of the disease if it was caused
by active imprinted genes. All 13 patients with distal ma-
ternal Ts14 (mTs14) were born SGA. Conversely, over
half of the patients with paternal Ts14 (pTs14) were born
at weights AGA, indicating that an absence of paternal
information likely causes growth retardation in patients
with UPD14. The minimum trisomic regions 14q31.1-
14qter and 14q24.3-14qter were identified as possibly
containing the imprinted genes [79]. Overall, the pheno-
type of patients with mUPD14 can be quite variable. A
review of 24 cases of patients displaying mUPD14 attri-
butes the growth retardation of these patients to con-
fined placental mosaicism and imprinted genes that
cause early skeletal maturation, although unusual pheno-
types may also be caused by autosomal, recessively inher-
ited mutations [80].
hGH treatment for SGA
Much research has correlated genetic mutations with SGA
births, but the ability to predict the effectiveness of hGH
therapy for each mutation remains controversial. Table 5
summarizes the various mutations that have been shown
to cause SGA and the likelihood that hGH therapy will
promote growth for individuals with these mutations
[11,13,16-18,23,25-29,39-47,51,53-55,57-62,68,70,74-76,78-
80]. Some patients with IGF-1 mutations have shown posi-
tive growth catch-up when treated with hGH therapy,
while others have shown better response to rhIGF-1 ther-
apy. Alternatively, the response to hGH therapy for
patients with IGF-1R mutations appears to correlate with
the type of mutation; patients with distal deletions of the
3hGH dose 67 mcg/kg/d
n=27






0 hGH dose 100 mcg/kg/d (2y)
n=8







0 21 3 5 6 y4
A
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Figure 2 (A) Amount of time required to increase height SD
score by 2 was 2.5 years for hGH therapy administered at a
dose of 67 mcg/kg/day and 5.5 years for hGH therapy
administered at a dose of 33 mcg/kg/day in children born SGA.
Figure 2A reprinted with permission from [82]. (B) After 6 years,
similar height SD scores were achieved using 2 years of high-dose
(100 mcg/kg/day) hGH therapy and 6 years of low-dose (33 mcg/kg/
day) hGH therapy for children born SGA. hGH, human growth
hormone; SD, standard deviation; SGA, small for gestational age.
Figure 2B reprinted with permission from [82].
Table 5 Summary of known genetic causes of SGA and the correlating response to hGH therapy [11,13,16-18,23,
25-29,39-47,51,53-55,57-62,68,70,74-76,78-80]
Class of genetic mutation Specific genetic variant Response to hGH therapy
IGF-1 Generally not effective
IGF-1R Good for partial distal deletions;
generally not effective for
point mutationsGH/IGF-1 axis Point
Distal
ALS deletions Good outcome for heterozygous carriers
Obesity/diabetes-related genes Unclear
Select Polymorphisms Angiotensinogen gene Unclear
d3-GHR Good outcome, but dose and age matter
SRS hGH therapy is commonly used for SRS,
but correlation between effectiveness
and specific genetic mutation has not
been carefully evaluated
Full mUPD7
UPD/imprinting effects mUPD7 for long arm of chromosome 7
Hypomethylation at ICR1 on 11p15
Duplication of ICR2 on 11p15
UPD14 Unclear
ALS, acid-labile subunit; ICR, imprinting control region; IGF-1, insulin-like growth factor-1; d3-GHR, deletion of exon 3 growth hormone receptor; hGH, human
growth hormone; SGA, small for gestational age; SRS, Silver-Russell syndrome; UPD, uniparental disomy.
Saenger and Reiter International Journal of Pediatric Endocrinology 2012, 2012:12 Page 8 of 12
http://www.ijpeonline.com/content/2012/1/12IGF-1R gene generally have improved GH-induced catch-
up growth as compared with patients who have IGF-1R
point mutations. Finally, the ability to predict the effective-
ness of hGH treatment depending on the specific disease
(eg, children with SRS versus children with UPD14) has
not been thoroughly reviewed, possibly because a signifi-
cant number of patients born SGA who undergo hGH
therapy are never genetically diagnosed. However, despite
the controversies, clinical studies have successfully eluci-
dated some trends about hGH treatment on growth in
children born SGA (as reviewed by Simon et al [81] and
Saenger et al [1]).
The rate of catch-up growth promoted by hGH ther-
apy in patients born SGA correlates with the dose;
higher doses typically afford rapid height increase, al-
though a similar response can be achieved using lower
doses for a longer time. For instance, a height gain of 2
SD was achieved for patients born SGA using doses of
either 67 mcg/kg/day over 2.5 years or 33 mcg/kg/day
over 5.5 years (Figure 2A) [82]. However, the low-dose
regimen requires three times as many injections and
50% more hGH overall than the high-dose method. The
method of administration of hGH therapy can also affect
height gain, though less significantly than dose. Patients
who received discontinuous high-dose hGH therapy (67
mcg/kg/day for one or two years) have shown slightly
increased height gain compared with patients receiving a
continuous low-dose regimen (33 mcg/kg/day doses for
three or four years), although discontinuation of the
treatment typically corresponds with reduction in
growth velocity [83]. A similar trend was observed previ-
ously by De Zeghers et al, who found that after six years,











Not stated −2.5 SD
Growth velocity
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FDA, United States Food and Drug Administration; EMEA, European Agency for
the Evaluation of Medicinal Products; hGH, human growth hormone; SDS,
standard deviation score; SGA, small for gestational age.
Reprinted with permission from [1].
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for two years and continuous low-dose hGH treatment
for six years (Figure 2B) [82].
In addition to the dose and method of administration,
the age of initiation of hGH therapy significantly affects
the outcome. Patients treated before the onset of pu-
berty achieve optimal results. A recent study showed
that children treated for one year with hGH therapy be-
fore the age of 4 years achieved greater height gain (1.7
SD score, 12.5 cm) than those treated after 4 years of
age (1.2 SD score) [84]. Even among older patients, this
trend persists. Patients receiving hGH therapy more
than two years before puberty showed increased height
gain (1.7 SD, ~12 cm) compared with patients treated
fewer than two years before puberty (0.9 SD gain, 6 cm).
However, nearly 90% of these patients achieved adult
height within the normal range [85]. Conversely, patients
treated during puberty achieved height gain of only 0.6
SD score, and fewer than 50% of these patients achieved
normal adult height [86].
In 2003, Ranke et al developed a model that essentially
summarized the trends that we have described and that
could be used by physicians to individualize hGH treat-
ment for SGA patients. Using a pharmacoepidemiologi-
cal survey of 613 children, various trends were
elucidated. In fact, the model could be used to explain
approximately 50% of the variability associated with
hGH therapy response during the first and second years
of treatment. Nearly 35% of the variability could be
attributed to the dose, followed by the patient’s age at
the start of treatment. Subsequent growth during the
second year of treatment could be predicted based on a
successful first year of treatment [87].
It must be mentioned, though not stressed, that some
controversy regarding the use of hGH arose in 2011 due
to results from a study conducted in France, the Santé
Adulte GH Enfant (SAGhE) study. The results from this
study indicated that long-term use of hGH in children
with short stature could increase a patient’s risk of death
[88]. The SAGhE study reported that hGH therapy, when
administered to patients at doses above 50 mcg/kg/day,
increased the risk of death by 30% as compared to the
general population in France. This effect was attributed to
an increased likelihood of bone-tumor formation, cardio-
vascular disease, and cerebrovascular events. These results
concerned patients born SGA, as the normal recom-
mended dose of hGH therapy can be approximately 70
mcg/kg/day (Table 6) [1]. However, recent publications
and an FDA report have noted flaws associated with the
SAGhE study design [88-90]. In many other long-term
evaluations of large groups of patients undergoing hGH
therapy, the overall safety profile is favorable [91-95]. No
increased risk of death due to leukemia, cancer, or cardio-
vascular disorders was observed.Conclusions
Based on results from more than 20 years of research, nu-
merous genetic causes for SGA births have been realized.
Genetic defects in either IGF-1 or IGF-1R that result in
SGA size typically correlate with phenotypical features
such as microcephaly and mental retardation. The most
predictive factors for IGF-1R deletion include small birth
size, head size, and stature, as well as high IGF-1 levels,
developmental delay, and micrognathia. hGH therapy in
patients with mutations in IGF-1 has shown moderate
success. Furthermore, for patients with IGF-1R mutations,
hGH treatment has been shown to be especially promis-
ing, particularly for those with distal deletions of the ter-
minal long arm of chromosome 15. Overall, in studies in
which the genotype of SGA patients was not known and
hGH therapy was conducted, improvements were
observed for most of the patient population, particularly if
therapy was begun at a young age.
However, despite these positive results, a number of
questions regarding the effectiveness of the treatment re-
main. For instance, hGH therapy for children with SRS
has shown positive results, but overall the improvements
are often not statistically significant. Furthermore, the
differences in SGA patient response to hGH therapy are
still only slightly understood. While much of the diver-
sity in response rates to hGH therapy for SGA patients
correlates with the type of genetic mutation, the role of
additional factors, such as ethnicity, on this treatment
still requires significant research.
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